GLIPIZIDE AND METFORMIN HYDROCHLORIDE

Post-LOE

glipizide and metformin hydrochloride

Teva

ANDAORALTABLET

Approved

Jan 2011

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

GLIPIZIDE AND METFORMIN HYDROCHLORIDE (glipizide and metformin hydrochloride) by Teva is mechanism of action: glipizide and metformin hydrochloride tablet combines glipizide and metformin hydrochloride, two antihyperglycemic agents with complementary mechanisms of action, to improve glycemic control in patients with type 2 diabetes. Approved for type 2 diabetes mellitus. First approved in 2011.

Drug data last refreshed 18h ago

Mechanism of Action

Mechanism of Action: Glipizide and metformin hydrochloride tablet combines glipizide and metformin hydrochloride, two antihyperglycemic agents with complementary mechanisms of action, to improve glycemic control in patients with type 2 diabetes. Glipizide appears to lower blood glucose acutely by…

Pharmacologic Class:

Sulfonylurea

Indications (1)

type 2 diabetes mellitus

Worked on GLIPIZIDE AND METFORMIN HYDROCHLORIDE at Teva? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.